Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.
Seattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is losing its research and development lead. In a Thursday filing with ...
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity ...
ANNOUNCER: 'Think Tank' has been made possible by Amgen, arecipient of the Presidential National Medal of Technology. Amgen,bringing better, healthier lives to people worldwide throughbiotechnology.
Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...